These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 25310357)

  • 1. Ezetimibe prevents the development of non‑alcoholic fatty liver disease induced by high‑fat diet in C57BL/6J mice.
    Wang X; Ren Q; Wu T; Guo Y; Liang Y; Liu S
    Mol Med Rep; 2014 Dec; 10(6):2917-23. PubMed ID: 25310357
    [TBL] [Abstract][Full Text] [Related]  

  • 2. P2Y2R Deficiency Ameliorates Hepatic Steatosis by Reducing Lipogenesis and Enhancing Fatty Acid β-Oxidation through AMPK and PGC-1α Induction in High-Fat Diet-Fed Mice.
    Dusabimana T; Park EJ; Je J; Jeong K; Yun SP; Kim HJ; Kim H; Park SW
    Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34073834
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ezetimibe prevents hepatic steatosis induced by a high-fat but not a high-fructose diet.
    Ushio M; Nishio Y; Sekine O; Nagai Y; Maeno Y; Ugi S; Yoshizaki T; Morino K; Kume S; Kashiwagi A; Maegawa H
    Am J Physiol Endocrinol Metab; 2013 Jul; 305(2):E293-304. PubMed ID: 23715726
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Selective Acetyl-CoA Carboxylase 1 Inhibitor Improves Hepatic Steatosis and Hepatic Fibrosis in a Preclinical Nonalcoholic Steatohepatitis Model.
    Tamura YO; Sugama J; Iwasaki S; Sasaki M; Yasuno H; Aoyama K; Watanabe M; Erion DM; Yashiro H
    J Pharmacol Exp Ther; 2021 Nov; 379(3):280-289. PubMed ID: 34535562
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Niemann-Pick C1 like 1 (NPC1L1) inhibitor ezetimibe improves metabolic disease via decreased liver X receptor (LXR) activity in liver of obese male mice.
    Sugizaki T; Watanabe M; Horai Y; Kaneko-Iwasaki N; Arita E; Miyazaki T; Morimoto K; Honda A; Irie J; Itoh H
    Endocrinology; 2014 Aug; 155(8):2810-9. PubMed ID: 24773344
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ezetimibe increases hepatic iron levels in mice fed a high-fat diet.
    Kishino Y; Tanaka Y; Ikeda T; Yamamoto K; Ogawa H; Iwatani Y; Kamisako T
    J Pharmacol Exp Ther; 2013 Jun; 345(3):483-91. PubMed ID: 23538201
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-hepatic steatosis activity of Sicyos angulatus extract in high-fat diet-fed mice and chemical profiling study using UHPLC-qTOF-MS/MS spectrometry.
    An JP; Choi JH; Huh J; Lee HJ; Han S; Noh JR; Kim YH; Lee CH; Oh WK
    Phytomedicine; 2019 Oct; 63():152999. PubMed ID: 31280138
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chronic administration of recombinant IL-6 upregulates lipogenic enzyme expression and aggravates high-fat-diet-induced steatosis in IL-6-deficient mice.
    Vida M; Gavito AL; Pavón FJ; Bautista D; Serrano A; Suarez J; Arrabal S; Decara J; Romero-Cuevas M; Rodríguez de Fonseca F; Baixeras E
    Dis Model Mech; 2015 Jul; 8(7):721-31. PubMed ID: 26035386
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ezetimibe improves high fat and cholesterol diet-induced non-alcoholic fatty liver disease in mice.
    Zheng S; Hoos L; Cook J; Tetzloff G; Davis H; van Heek M; Hwa JJ
    Eur J Pharmacol; 2008 Apr; 584(1):118-24. PubMed ID: 18329014
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Downregulated microRNA-130b-5p prevents lipid accumulation and insulin resistance in a murine model of nonalcoholic fatty liver disease.
    Liu X; Chen S; Zhang L
    Am J Physiol Endocrinol Metab; 2020 Jul; 319(1):E34-E42. PubMed ID: 32228319
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ezetimibe decreases SREBP-1c expression in liver and reverses hepatic insulin resistance in mice fed a high-fat diet.
    Muraoka T; Aoki K; Iwasaki T; Shinoda K; Nakamura A; Aburatani H; Mori S; Tokuyama K; Kubota N; Kadowaki T; Terauchi Y
    Metabolism; 2011 May; 60(5):617-28. PubMed ID: 20673929
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Yangonin protects against non-alcoholic fatty liver disease through farnesoid X receptor.
    Dong R; Yang X; Wang C; Liu K; Liu Z; Ma X; Sun H; Huo X; Fu T; Meng Q
    Phytomedicine; 2019 Feb; 53():134-142. PubMed ID: 30668392
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Psoralea corylifolia L. extract ameliorates nonalcoholic fatty liver disease in free-fatty-acid-incubated HEPG2 cells and in high-fat diet-fed mice.
    Hong Y; Choi SI; Hong E; Kim GH
    J Food Sci; 2020 Jul; 85(7):2216-2226. PubMed ID: 32579753
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sesamin ameliorates nonalcoholic hepatic steatosis by inhibiting CD36-mediated hepatocyte lipid accumulation in vitro and in vivo.
    Bai YP; Zhang T; Hu ZY; Zhang Y; Wang DG; Zhou MY; Zhang Y; Zhang F; Kong X
    Biochem Pharmacol; 2024 Jun; 224():116240. PubMed ID: 38679210
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pu-erh tea extract ameliorates high-fat diet-induced nonalcoholic steatohepatitis and insulin resistance by modulating hepatic IL-6/STAT3 signaling in mice.
    Cai X; Fang C; Hayashi S; Hao S; Zhao M; Tsutsui H; Nishiguchi S; Sheng J
    J Gastroenterol; 2016 Aug; 51(8):819-29. PubMed ID: 26794005
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Thrombospondin 1 improves hepatic steatosis in diet-induced insulin-resistant mice and is associated with hepatic fat content in humans.
    Bai J; Xia M; Xue Y; Ma F; Cui A; Sun Y; Han Y; Xu X; Zhang F; Hu Z; Liu Z; Liu Y; Cai G; Su W; Sun X; Wu H; Yan H; Chang X; Hu X; Bian H; Xia P; Gao J; Li Y; Gao X
    EBioMedicine; 2020 Jul; 57():102849. PubMed ID: 32580141
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chokeberry attenuates the expression of genes related to de novo lipogenesis in the hepatocytes of mice with nonalcoholic fatty liver disease.
    Park H; Liu Y; Kim HS; Shin JH
    Nutr Res; 2016 Jan; 36(1):57-64. PubMed ID: 26773781
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lipid-lowering agents inhibit hepatic steatosis in a non-alcoholic steatohepatitis-derived hepatocellular carcinoma mouse model.
    Orime K; Shirakawa J; Togashi Y; Tajima K; Inoue H; Nagashima Y; Terauchi Y
    Eur J Pharmacol; 2016 Feb; 772():22-32. PubMed ID: 26724391
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapeutic Effect of Gypenosides on Nonalcoholic Steatohepatitis via Regulating Hepatic Lipogenesis and Fatty Acid Oxidation.
    Li H; Ying H; Hu A; Hu Y; Li D
    Biol Pharm Bull; 2017; 40(5):650-657. PubMed ID: 28458350
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pathophysiological importance of bile cholesterol reabsorption: hepatic NPC1L1-exacerbated steatosis and decreasing VLDL-TG secretion in mice fed a high-fat diet.
    Toyoda Y; Takada T; Yamanashi Y; Suzuki H
    Lipids Health Dis; 2019 Dec; 18(1):234. PubMed ID: 31883528
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.